— News and commentary from the endocrinology world
June 2, 2026
• 2 min read
Insulet initiated a voluntary device correction of certain Omnipod pods due to a manufacturing defect that causes insulin to leak rather than being fully delivered into the body, the FDA alerted. This action is separate from the company's correction issued in March.
The agency also expanded approval of inhaled mealtime insulin (Afrezza) to include children ages 6 years and older with type 1 and type 2 diabetes, said maker MannKind.
